Search Results - "Meert, Liv"

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial by Selleslag, Dominik, Suciu, Stefan, Meloni, Giovanna, Muus, Petra, Halkes, Constantijn J M, Venditti, Adriano, Ramadan, Safaa M, Pruijt, Hans, Meert, Liv, Vignetti, Marco, Marie, Jean-Pierre, Wittnebel, Sébastian, de Witte, Theo, Amadori, Sergio, Willemze, Roelof, Baron, Frédéric

Get full text

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial by Amadori, Sergio, Suciu, Stefan, Selleslag, Dominik, Aversa, Franco, Gaidano, Gianluca, Musso, Maurizio, Annino, Luciana, Venditti, Adriano, Voso, Maria Teresa, Mazzone, Carla, Magro, Domenico, De Fabritiis, Paolo, Muus, Petra, Alimena, Giuliana, Mancini, Marco, Hagemeijer, Anne, Paoloni, Francesca, Vignetti, Marco, Fazi, Paola, Meert, Liv, Ramadan, Safaa Mahmoud, Willemze, Roel, de Witte, Theo, Baron, Frédéric

“…To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care (BSC) including hydroxyurea as first-line therapy in older patients with acute…”
Get full text

Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer by Maertens, Johan, Lodewyck, Tom, Donnelly, J Peter, Chantepie, Sylvain, Robin, Christine, Blijlevens, Nicole, Turlure, Pascal, Selleslag, Dominik, Baron, Frédéric, Aoun, Mickael, Heinz, Werner J, Bertz, Hartmut, Ráčil, Zdeněk, Vandercam, Bernard, Drgona, Lubos, Coiteux, Valerie, Llorente, Cristina Castilla, Schaefer-Prokop, Cornelia, Paesmans, Marianne, Ameye, Lieveke, Meert, Liv, Cheung, Kin Jip, Hepler, Deborah A, Loeffler, Jürgen, Barnes, Rosemary, Marchetti, Oscar, Verweij, Paul, Lamoth, Frederic, Bochud, Pierre-Yves, Schwarzinger, Michael, Cordonnier, Catherine

“…Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive,…”
Get full text

High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial by WILLEMZE, Roelof, SUCIU, Stefan, FABBIANO, Francesco, NOBILE, Francesco, SBORGIA, Marco, CAMERA, Andrea, SELLESLAG, Dominik L. D, LEFRERE, Francois, MAGRO, Domenico, SICA, Simona, CANTORE, Nicola, BEKSAC, Meral, MELONI, Giovanna, BERNEMAN, Zwi, THOMAS, Xavier, MELILLO, Lorella, GUIMARAES, Jose E, LEONI, Pietro, LUPPI, Mario, MITRA, Maria E, BRON, Dominique, FILLET, Georges, MARIJT, Erik W. A, LABAR, Boris, VENDITTI, Adriano, HAGEMEIJER, Anne, MANCINI, Marco, JANSEN, Joop, CILLONI, Daniela, MEERT, Liv, FAZI, Paola, VIGNETTI, Marco, TRISOLINI, Silvia M, MANDELLI, Franco, JEAN-PIERRE, Marie, DE WITTE, Theo, HALKES, Constantijn J. M, MUUS, Petra, MISTRIK, Martin, AMADORI, Sergio, SPECCHIA, Giorgina

“…Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of…”
Get full text

Empiric versus pre-emptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: a randomized trial of the European organization for Research and Treatment of cancer (EORTC 65091) by Maertens, Johan, Lodewyck, Tom, Peter Donnelly, J., Chantepie, Sylvain, Robin, Christine, Blijlevens, Nicole, Turlure, Pascal, Selleslag, Dominik, Baron, Frederic, Aoun, Mickael, Heinz, Werner J., Bertz, Hartmut, Racil, Zdenek, Vandercam, Bernard, Drgona, Lubos, Coiteux, Valerie, Llorente, Cristina Castilla, Schaefer-Prokop, Cornelia, Paesmans, Marianne, Ameye, Lieveke, Meert, Liv, Cheung, Kin Jip, Hepler, Deborah A., Loeffler, Jurgen, Barnes, Rosemary, Marchetti, Oscar, Verweij, Paul, Lamoth, Frederic, Bochud, Pierre Yves, Schwarzinger, Michael, Cordonnier, Catherine

“…BACKGROUND: Empiric antifungal therapy is considered the standard-of-care for high-risk neutropenic patients with persistent fever. The impact of a…”
Get full text

Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase III study by Baron, Frédéric, Efficace, Fabio, Cannella, Laura, Muus, Petra, Trisolini, Silvia, Halkes, Constantijn J. M., Fazi, Paola, Vignetti, Marco, Marie, Jean‐Pierre, Chiusolo, Patrizia, Velden, Walter, La Sala, Edoardo, Vitolo, Umberto, Thomas, Xavier, Lefrère, Francois, Di Raimondo, Francesco, Bourhis, Jean‐Henri, Specchia, Giorgina, Guimarães, José E., Allione, Bernardino, Vrhovac, Radovan, Ferrara, Felicetto, Stevens‐Kroef, Marian, Meert, Liv, Witte, Theo, Willemze, Roelof, Amadori, Sergio, Suciu, Stefan

“…We provide a long‐term evaluation of patients enrolled in the EORTC/GIMEMA AML‐10 trial which included a total of 2157 patients, 15‐60 years old, randomized to…”
Get full text

Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013) by de Witte, Theo, Suciu, Stefan, Meert, Liv, Halkes, Constantijn, Selleslag, Dominik, Bron, Dominique, Amadori, Sergio, Willemze, Roel, Muus, Petra, Baron, Frédéric

“…The primary objective of this trial was to assess the feasibility, toxicity profile, and antitumor activity of gemtuzumab ozogamicin (GO) combined with a…”
Get full text

Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials by Ramadan, Safaa M., Suciu, Stefan, Stevens-Kroef, Marian J. P. L., Willemze, Roelof, Amadori, Sergio, de Witte, Theo, Löwenberg, Bob, Muus, Petra, Labar, Boris, Meert, Liv, de Schaetzen, Gaetan, Meloni, Giovanna, Leone, Giuseppe, Vignetti, Marco, Marie, Jean-Pierre, Lübbert, Michael, Baron, Frédéric

“…We report the outcomes of secondary acute myeloid leukemia (s-AML) patients included in one of 13 European Organisation for Research and Treatment of Cancer…”
Get full text

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial by Selleslag, Dominik L.D., Suciu, Stefan, Meloni, Giovanna, Muus, Petra, Halkes, Constantijn J.M., Venditti, Adriano, Ramadan, Safaa M, Pruijt, Hans, Meert, Liv, Vignetti, Marco, Marie, Jean-Pierre, Bron, Dominique, de Witte, Theo, Amadori, Sergio, Willemze, Roelof, Baron, Frederic

“…RW and FB are co-senior authors. Background: The prognosis of younger patients with intermediate/bad risk AML or high-risk MDS remains unsatisfactory. Although…”
Get full text

Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials by Ramadan, Safaa M., Suciu, Stefan, Stevens-Kroef, Marian J.P.L., Willemze, Roelof, Amadori, Sergio, de Witte, Theo, Lowenberg, Bob, Muus, Petra, Labar, Boris, Meert, Liv, de Schaetzen, Gaetan, Meloni, Giovanna, Leone, Giuseppe, Vignetti, Marco, Mandelli, Franco, Baron, Frederic, Marie, Jean-Pierre

“…▪ Secondary acute myeloid leukemia (sAML) describes patients (pts) with a history of malignant or non-malignant disease or AML secondary to environmental,…”
Get full text

Improved Overall Survival with Gemtuzumab Ozogamicin (GO) Compared with Best Supportive Care (BSC) in Elderly Patients with Untreated Acute Myeloid Leukemia (AML) Not Considered Fit for Intensive Chemotherapy: Final Results from the Randomized Phase III Study (AML-19) of the EORTC and Gimema Leukemia Groups by Amadori, Sergio, Suciu, Stefan, Selleslag, Dominik, Rossetti, Elena, Gaidano, Gianluca, Musso, Maurizio, Annino, Luciana, Venditti, Adriano, Magro, Domenico, de Fabritiis, Paolo, Muus, Petra, Alimena, Giuliana, Mancini, Marco, Hagemeijer, Anne, Cotugno, Francesca, Vignetti, Marco, Fazi, Paola, Meert, Liv, Ramadan, Safaa M, Willemze, Roelof, de Witte, Theo, Baron, Frederic

“…▪ Background: An unmet medical need persists for elderly patients (pts) with AML who are deemed not to be fit for intensive chemotherapy. Such pts are usually…”
Get full text

Clofarabine in Combination with a Standard Remission Induction Regimen (AraC and idarubicin) in Patients with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS):Phase I Results of An Ongoing Phase I/II Study of the EORTC-LG and GIMEMA(EORTC GIMEMA 06061/AML-14A trial) by Willemze, Roelof, Muus, Petra, Halkes, Stijn J.M., Meloni, Giovanna, Suciu, Stefan, Meert, Liv, Flament, Jocelyne, Karrasch, Matthias, Vignetti, Marco, Amadori, Sergio, de Witte, Theo M., Marie, Jean-Pierre

“…Abstract 2610 Remission induction treatment in previously untreated intermediate/bad risk AML or high risk MDS needs continuous improvement. Clofarabine is a…”
Get full text

Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011 by Lübbert, Michael, Suciu, Stefan, Hagemeijer, Anne, Bogatyreva, Ljudmila, Rüter, Björn, Platzbecker, Uwe, Giagounidis, Aristoteles, Selleslag, Dominik, Labar, Boris, Germing, Ulrich, Salih, Helmut R, Meert, Liv, Muus, Petra, Pflüger, Karl-Heinz, Kuendgen, Andrea, Aul, Carlo, de Witte, Theo M., Ganser, Arnold, Marie, Jean-Pierre, Wijermans, Pierre W.

“…Abstract 2804 The “monosomal karyotype” cytogenetic subgroup (MK+), as defined by Breems et al. (1) encompasses mostly complex karyotypes (CK, >3…”
Get full text

Clofarabine in combination with a standard remission induction regimen in patients 18-60 years old previously untreated intermediate an bad risk actue myelogenous leukemia (AML) or high risk myelodysplasia (MDS): combined phase I/II results of the EORTC/Gimema AML-14A trial by SELLESLAG, Dominik L.D., SUCIU, Stefan, MELONI, Giovanna, MUUS, Petra, HALKES, Constantijn J.M., VENDITTI, Adriano, RAMADAN, Safaa M., PRUIJT, Hans, MEERT, Liv, VIGNETTI, Marco, MARIE, Jean-Pierre, BRON, Dominique, DE WITTE, Theo, AMADORI, Sergio, WILLEMZE, Roelof, BARON, Frédéric

Get full text

Improved overall survival with Gemtuzumab Ozogamicin (GO) compared with best supportive care (BSC) in elderly patients with untreated acute myeloid leukemia (AML) not considered fit for intensive chemotherapy: final results from the randomized phase III study (AML-19) of the EORTC and gimema leukemia groups by AMADORI, Sergio, SUCIU, Stefan, SELLESLAG, Dominik, ROSSETTI, Elena, GAIDANO, Gianluca, MUSSO, Maurizio, ANNINO, Luciana, VENDITTI, Adriano, MAGRO, Domenico, DE FABRITIIS, Paolo, MUUS, Petra, ALIMENA, Giuliana, MANCINI, Marco, HAGEMEIJER, Anne, COTUGNO, Francesca, VIGNETTI, Marco, FAZI, Paola, MEERT, Liv, RAMADAN, Safaa M., WILLEMZE, Roelof, DE WITTE, Theo, BARON, Frédéric

Get full text

Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials by RAMADAN, Safaa M., SUCIU, Stefan, STEVENS-KROEF, Marian J.P.L., WILLEMZE, Roelof, AMADORI, Sergio, DE WITTE, Theo, LOWENBERG, Bob, MUUS, Petra, LABAR, Boris, MEERT, Liv, DE SCHAETZEN, Gaetan, MELONI, Giovanna, LEONE, Giuseppe, VIGNETTI, Marco, MANDELLI, Franco, BARON, Frédéric, MARIE, Jean-Pierre

Get full text